Systemic Lupus Erythematosus
Overview
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1306974-systemic-lupus-erythematosus-pipeline-review-h1-2017
Systemic Lupus Erythematosus Industry Major Outlook
The Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 26, 28, 1, 44, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.
Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
Table of Contents
Table of Contents 2
Introduction 6
Systemic Lupus Erythematosus - Overview 7
Systemic Lupus Erythematosus - Therapeutics Development 8
Systemic Lupus Erythematosus - Therapeutics Assessment 24
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 38
Systemic Lupus Erythematosus - Drug Profiles 78
Systemic Lupus Erythematosus - Dormant Projects 379
Systemic Lupus Erythematosus - Discontinued Products 384
Systemic Lupus Erythematosus - Product Development Milestones 386
Appendix 395
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1306974-systemic-lupus-erythematosus-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Overview
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1306974-systemic-lupus-erythematosus-pipeline-review-h1-2017
Systemic Lupus Erythematosus Industry Major Outlook
The Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 26, 28, 1, 44, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.
Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
Table of Contents
Table of Contents 2
Introduction 6
Systemic Lupus Erythematosus - Overview 7
Systemic Lupus Erythematosus - Therapeutics Development 8
Systemic Lupus Erythematosus - Therapeutics Assessment 24
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 38
Systemic Lupus Erythematosus - Drug Profiles 78
Systemic Lupus Erythematosus - Dormant Projects 379
Systemic Lupus Erythematosus - Discontinued Products 384
Systemic Lupus Erythematosus - Product Development Milestones 386
Appendix 395
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1306974-systemic-lupus-erythematosus-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
No comments:
Post a Comment